SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Olofsson Joakim)
 

Sökning: WFRF:(Olofsson Joakim) > Chemokine Analysis ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006130naa a2200493 4500
001oai:DiVA.org:uu-512777
003SwePub
008231004s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:237377898
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5127772 URI
0247 a https://doi.org/10.1158/2767-9764.CRC-22-04902 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2373778982 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Sah, Vasu R.u Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Gothenburg, Sweden.4 aut
2451 0a Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
264 1b American Association For Cancer Research (AACR),c 2023
338 a electronic2 rdacarrier
520 a Purpose: Patients with metastatic uveal melanoma have limited therapeutic options and high mortality rate so new treatment options are needed.Patients and Methods: We previously reported that patients treated with the PD-1 inhibitor pembrolizumab and the histone deacetylase inhibitor entinostat in the PEMDAC trial, experienced clinical benefits if their tu-mor originated from iris or was wildtype for BAP1 tumor suppressor gene. Here we present the 2-year follow-up of the patients in the PEMDAC trial and identify additional factors that correlate with response or survival.Results: Durable responses were observed in 4 patients, with additional 8 patients exhibiting a stable disease. The median overall survival was 13.7 months. Grade 3 adverse events were reported in 62% of the patients, but they were all manageable. No fatal toxicity was observed. Activity of thymidine kinase 1 in plasma was higher in patients with stable disease or who progressed on treatment, compared with those with partial response. Chemokines and cytokines were analyzed in plasma. Three chemokines were significantly different when comparing patients with and without response. One of the factors, CCL21, was higher in the plasma of respond-ing patients before treatment initiation but decreased in the same patients upon treatment. In tumors, CCL21 was expressed in areas resembling ter -tiar y lymphoid structures (TLS). High plasma levels of CCL21 and presence of TLS-like regions in the tumor correlated with longer survival.Conclusions: This study provides insight into durable responses in the PEMDAC trial, and describes dynamic changes of chemokines and cytokines in the blood of these patients.Significance: The most significant finding from the 2-year follow-up study of the PEMDAC trial was that high CCL21 levels in blood was associated with response and survival. CCL21 was also expressed in TLS-like regions and presence of these regions was associated with longer survival. These analyses of soluble and tumor markers can inform on predictive biomark-ers needing validation and become hypothesis generating for experimental research.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Jespersen, Henriku Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.;Oslo Univ Hosp, Dept Oncol, Oslo, Norway.4 aut
7001 a Karlsson, Joakimu Univ Western Australia, Harry Perkins Inst Med Res, Perth, WA, Australia.4 aut
7001 a Nilsson, Lisa M.u Univ Western Australia, Harry Perkins Inst Med Res, Perth, WA, Australia.4 aut
7001 a Bergqvist, Mattiasu Biovica Int AB, Uppsala Sci Pk, Uppsala, Sweden.4 aut
7001 a Johansson, Ivau Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.4 aut
7001 a Carneiro, Anau Skane Univ Hosp, Dept Oncol, Lund, Sweden.4 aut
7001 a Helgadottir, Hilduru Karolinska Institutet,Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.4 aut
7001 a Levin, Maxu Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.4 aut
7001 a Ullenhag, Gustavu Uppsala universitet,Cancerimmunterapi4 aut0 (Swepub:uu)gustulle
7001 a Stahlberg, Andersu Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Dept Lab Med, Gothenburg, Sweden.;Univ Gothenburg, Inst Biomed, Sahlgrenska Ctr Canc Res, Dept Clin Genet & Genom, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Gothenburg, Sweden.4 aut
7001 a Bagge, Roger Olofssonu Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Surg, Gothenburg, Sweden.;Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden.4 aut
7001 a Nilsson, Jonas A.u Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Gothenburg, Sweden.4 aut
7001 a Ny, Larsu Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.4 aut
7102 a Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Gothenburg, Sweden.b Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.;Oslo Univ Hosp, Dept Oncol, Oslo, Norway.4 org
7730 t Cancer Research Communicationsd : American Association For Cancer Research (AACR)g 3:5, s. 884-895q 3:5<884-895x 2767-9764
8564 u https://doi.org/10.1158/2767-9764.CRC-22-0490y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1802376/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512777
8564 8u https://doi.org/10.1158/2767-9764.CRC-22-0490
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:237377898

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy